Jodi Dettman
Adult Health · Edgewood, NMNPI 1720269178
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Novo Nordisk at 34.5% of the total. Reporting peaked in 2022 at $611 and has fallen 69.3% since, to $187 in 2025.
Across 64 payments — averaging $26.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$576
- AbbVie$318
- Philips North America LLC$142
- Lilly USA, LLC$116
- Organon$102
- Pfizer$81
- plus $335 from 8 others
What the payments were for
- Food & beverage$1,668100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 14 | $576 |
| AbbVie | 18 | $318 |
| Philips North America LLC | 3 | $142 |
| Lilly USA, LLC | 6 | $116 |
| Organon | 2 | $102 |
| Pfizer | 5 | $81 |
| Mylan Specialty L.p. | 4 | $69 |
| Teva Pharmaceuticals USA, Inc. | 3 | $62 |
| Exact Sciences | 2 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $33 |
| Apria Healthcare LLC | 1 | $32 |
| Viatris Specialty LLC | 1 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,668 in reported general payments places this provider in the 80th percentile of 52 adult health providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $37,877 |
| UbrelvyUbrogepant | 12 | $35,154 |
| Aimovig AutoinjectorErenumab-Aooe | 24 | $17,651 |
| JardianceEmpagliflozin | 17 | $17,345 |
| LinzessLinaclotide | 20 | $16,334 |
| XareltoRivaroxaban | 11 | $14,538 |
| Insulin Aspart FlexpenInsulin Aspart | 13 | $4,777 |
| Fluticasone Propionate HfaFluticasone Propionate | 13 | $3,846 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $2,495 |
| Gabapentin | 120 | $2,200 |
| Oxycodone Hcl | 98 | $2,021 |
| Levothyroxine Sodium | 180 | $1,968 |
| Duloxetine Hcl | 59 | $1,953 |
| Atorvastatin Calcium | 109 | $1,914 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 103 | $1,910 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Linzess | $318 | $51,48832 claims |
| PfizerEliquis | $81 | $37,87729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 52 adult health providers in New Mexico.
Other adult health in Edgewood
- Elizabeth EvansAlbuquerque$9K
- Leslie DorkAlbuquerque$7K
- Stephanie MahootyAlbuquerque$6K
- Debra NarcisseAlbuquerque$5K
- Kimberly MillerLas Cruces$3K
- Sara RogersAlbuquerque$2K
- Theresa CastlemainAlbuquerque$2K
- Sharlene RogersAlamogordo$2K
- Deborah CaswellSanta Fe$2K
- Guadalupe TelfordLas Cruces$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.